7/10/2013

GlaxoSmithKline filed an application with the FDA for approval to market a combination of dabrafenib and trametinib as a treatment for melanoma. The application is supported by data from a Phase I/II trial. Dabrafenib and trametinib, sold under the brand names Tafinlar and Mekinist, respectively, were individually approved by the FDA in May.

Full Story:
Reuters

Related Summaries